|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017921,
umls-concept:C0205390,
umls-concept:C0242383,
umls-concept:C0600518,
umls-concept:C0796392,
umls-concept:C1274040,
umls-concept:C1314792,
umls-concept:C1412379,
umls-concept:C1517572,
umls-concept:C1656863,
umls-concept:C2603343
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2006-9-27
|
|
pubmed:abstractText |
To evaluate the safety of three dose regimens of intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) for the management of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0146-0404
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4569-78
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17003454-Aged,
pubmed-meshheading:17003454-Aged, 80 and over,
pubmed-meshheading:17003454-Angiogenesis Inhibitors,
pubmed-meshheading:17003454-Antibodies, Monoclonal,
pubmed-meshheading:17003454-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17003454-Choroidal Neovascularization,
pubmed-meshheading:17003454-Dose-Response Relationship, Drug,
pubmed-meshheading:17003454-Female,
pubmed-meshheading:17003454-Fluorescein Angiography,
pubmed-meshheading:17003454-Follow-Up Studies,
pubmed-meshheading:17003454-Humans,
pubmed-meshheading:17003454-Injections,
pubmed-meshheading:17003454-Macular Degeneration,
pubmed-meshheading:17003454-Male,
pubmed-meshheading:17003454-Middle Aged,
pubmed-meshheading:17003454-Prospective Studies,
pubmed-meshheading:17003454-Tomography, Optical Coherence,
pubmed-meshheading:17003454-Treatment Outcome,
pubmed-meshheading:17003454-Vascular Endothelial Growth Factor A,
pubmed-meshheading:17003454-Visual Acuity,
pubmed-meshheading:17003454-Vitreous Body
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
|
|
pubmed:affiliation |
U.D.A.T. Macular Imaging and Treatment Division, Hospital de Olhos de Araraquara, Araraquara, SP, Brazil. roger.retina@globo.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
